siRNA Blocking of Mammalian Target of Rapamycin (mTOR) Attenuates Pathology in Annonacin-Induced Tauopathy in Mice.
Autophagy
Neurodegeneration
Tauopathy
mTOR
siRNA
Journal
Neurotoxicity research
ISSN: 1476-3524
Titre abrégé: Neurotox Res
Pays: United States
ID NLM: 100929017
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
24
09
2018
accepted:
19
10
2018
revised:
16
10
2018
pubmed:
27
10
2018
medline:
24
5
2019
entrez:
27
10
2018
Statut:
ppublish
Résumé
Tauopathy is a pathological hallmark of many neurodegenerative diseases. It is characterized by abnormal aggregates of pathological phosphotau and somatodendritic redistribution. One suggested strategy for treating tauopathy is to stimulate autophagy, hence, getting rid of these pathological protein aggregates. One key controller of autophagy is mTOR. Since stimulation of mTOR leads to inhibition of autophagy, inhibitors of mTOR will cause stimulation of autophagy process. In this report, tauopathy was induced in mice using annonacin. Blocking of mTOR was achieved through stereotaxic injection of siRNA against mTOR. The behavioral and immunohistochemical evaluation revealed the development of tauopathy model as proven by deterioration of behavioral performance in open field test and significant tau aggregates in annonacin-treated mice. Blocking of mTOR revealed significant clearance of tau aggregates in the injected side; however, tau expression was not affected by mTOR blockage.
Identifiants
pubmed: 30362086
doi: 10.1007/s12640-018-9974-3
pii: 10.1007/s12640-018-9974-3
doi:
Substances chimiques
Furans
0
Lactones
0
RNA, Small Interfering
0
annonacin
40372ET6TM
mTOR protein, mouse
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
987-992Subventions
Organisme : Science and Technology Development Fund (STDF)
ID : BARG 13892
Références
Science. 2000 Dec 1;290(5497):1717-21
pubmed: 11099404
Science. 2005 Jul 15;309(5733):476-81
pubmed: 16020737
FEBS J. 2005 Aug;272(16):4211-20
pubmed: 16098202
Autophagy. 2005 Oct-Dec;1(3):131-40
pubmed: 16874025
Autophagy. 2008 Oct;4(7):851-65
pubmed: 18670193
Eur J Neurol. 2009 Mar;16(3):297-309
pubmed: 19364361
Autophagy. 2011 Apr;7(4):412-25
pubmed: 21193837
Cell. 2012 Apr 13;149(2):274-93
pubmed: 22500797
J Biol Chem. 2013 May 31;288(22):15556-70
pubmed: 23585566
PLoS One. 2013 May 07;8(5):e62459
pubmed: 23667480
Lancet Neurol. 2013 Jun;12(6):609-22
pubmed: 23684085
J Cell Biol. 2013 Nov 25;203(4):563-74
pubmed: 24385483
Exp Neurol. 2014 Mar;253:113-25
pubmed: 24389273
Neuropharmacology. 2014 Oct;85:121-30
pubmed: 24880087
J Neurosci. 2014 Jun 4;34(23):7988-98
pubmed: 24899720
Neurobiol Dis. 2014 Oct;70:224-36
pubmed: 25014022
PLoS One. 2014 Dec 01;9(12):e113557
pubmed: 25437199
Curr Gene Ther. 2014;14(5):343-51
pubmed: 25687501
Oncotarget. 2015 Sep 15;6(27):23052-4
pubmed: 26375366
PLoS One. 2015 Nov 05;10(11):e0142340
pubmed: 26540269
J Neurochem. 2016 Nov;139(4):624-639
pubmed: 27569447
Metab Brain Dis. 2018 Apr;33(2):583-587
pubmed: 29080085